Latus Bio Appointed New Board Leaders
The Philadelphia-based developer of gene therapies has added pharmaceutical and financial expertise to its board.
Updated on Sept. 19, 2026 in Biotech
Live Poll
Do you trust biotechnology companies to effectively develop and bring new gene therapies to patients?
Latus Bio has appointed Donald Hayden as board chairman and Michael MacLean as an independent director and Audit Committee chair. The company is currently transitioning into a clinical-stage enterprise focused on gene therapies for CLN2 and Huntington's disease.
Why it matters
These appointments bring significant pharmaceutical operating and transaction experience to Latus Bio as the firm approaches clinical milestones for its lead programs. The leadership expansion supports the company's shift toward testing its gene therapies in human subjects.
Latus Bio is developing LTS-101 for CLN2 disease and LTS-201 for Huntington's disease using AAV capsid variants to deliver therapies at low doses. These adeno-associated virus (AAV) vectors—modified, non-pathogenic viruses used as genetic delivery vehicles—are being advanced into clinical trials.
The players
Latus Bio
A Philadelphia-based biotech firm developing AAV-based gene therapies for neurological conditions.
Donald Hayden
A veteran executive who previously served as president of Global Pharmaceuticals at Bristol Myers Squibb.
Michael MacLean
A financial executive who previously served as chief financial officer for Avidity Biosciences.
The details
The company utilizes AAV capsid variants to improve the delivery of its gene therapy candidates. By modifying the protein shell of the virus, Latus Bio aims to transport genetic material into target cells more efficiently at lower doses. This technical strategy is central to their effort to move LTS-101 and LTS-201 from the bench into clinical-stage testing.
Timeline
2008: Donald Hayden began his tenure as chairman for Otsuka America Pharmaceutical.
2025: Eli Lilly completed the acquisition of Verve Therapeutics.
2026: Novartis acquired Avidity Biosciences for more than $12 billion.
September 19, 2026: Latus Bio announced the new board appointments.
The Tech Race
Latus Bio enters a competitive landscape defined by the increasing use of AAV capsids for targeting neurodegenerative diseases. Its move to secure seasoned financial leadership follows a series of high-value industry acquisitions, including Novartis's $12 billion purchase of Avidity Biosciences.
The transition to a clinical-stage company signifies that Latus Bio is moving toward active human research programs rather than purely laboratory-based development. Patients and families affected by CLN2 and Huntington's disease should watch for updates regarding future clinical trial recruitment.
The takeaway
Latus Bio is signaling its readiness to advance its lead genetic programs through human trials by securing experienced leadership. Investors and researchers should monitor the company's upcoming filings for data on clinical progress for its LTS-101 and LTS-201 candidates.
Further reading
For more on the regional ecosystem, visit our Biotech section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust biotechnology companies to effectively develop and bring new gene therapies to patients?
